Certain obesity drugs will cost as little as $149 and Medicare will start covering them under White House deals

U.S. President Donald Trump, in front of Novo Nordisk CEO Maziar Mike Doustdar and Eli Lilly CEO David A. Ricks, makes an announcement from the Oval Office at the White House in Washington, D.C., U.S. November 6, 2025. REUTERS/Jonathan Ernst Jonathan Ernst/Reuters

Certain blockbuster obesity drugs will be available for as little as $149 per month and more Medicare enrollees will have access to them under two deals announced Thursday by the Trump administration.

The arrangements with drugmakers Eli Lilly and Novo Nordisk, which President Donald Trump foreshadowed in remarks last month, are the latest in the administration’s efforts to lower drug prices. As part of the new deals, the drugmakers have also agreed to reduce prices for a wider array of drugs in Medicaid and the list pric